RxDoctor Payments Data

Patricia Desjarlais

Psychiatric/Mental Health · Alexandria Bay, NYNPI 1962886812

Payments from drug & device makers

$1,948in general payments, 2019–2025

Across 98 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Sunovion Pharmaceuticals Inc.$270
  • AbbVie$144
  • Johnson & Johnson$108
  • Neurocrine Biosciences, Inc.$101
  • Axsome Therapeutics, Inc.$73
  • plus $143 from 4 others

What the payments were for

  • Food & beverage$1,85295%
  • Education$965%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,948 in reported general payments places this provider in the 75th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$1,620
Medicare patients
16
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl21$29,828
Lurasidone Hcl19$8,543
TrintellixVortioxetine Hydrobromide14$6,900
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine15$1,308
Bupropion XlBupropion Hcl49$901
Hydroxyzine Hcl23$539
Aripiprazole33$522
Duloxetine Hcl32$512
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine11$507
Quetiapine Fumarate36$407
Doxepin Hcl18$381
Clonazepam25$378
Prazosin Hcl11$372
Venlafaxine Hcl ErVenlafaxine Hcl22$352
Sertraline Hcl52$290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$144$29,82821 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$58$6,90014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Alexandria Bay

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →